Linezolid for Treatment of Nontuberculous Mycobacterial Diseases

Inclusion Criteria: * Diagnosis of non-tuberculous mycobacterial (NTM) diseases * Active or stable diseases receiving either parenteral or oral antimycobacterial treatment * Require at least more than 6 months of treatment from enrollment Exclusion Criteria: * Stable NTM diseases with a plan to discontinue treatment within 3 months * History of allergy to linezolid * Hemoglobin \< 7 g/dl) or total white blood count \< 3,000 /cu.mm. or thrombocytopenia \< 50,000 cells/cu.mm. * Concomitant uses of serotoninergic drugs (SSRIs) or Monoamine oxidase inhibitor (MAOIs) within 30 days prior to enrollment * Abnormal neurological findings such as numbness, abnormal vision etc.